1. One-stop Drug Screening
  2. Screening Libraries
  3. Cell-based Compound Screening

Cell Phenotype-Based Activity Screening

Cell phenotype-based drug screening targets the overall function and behavior of cells (phenotype), focusing on the effects of drugs on characteristics such as cell growth, migration, apoptosis, differentiation, metabolism, and morphology, rather than targeting specific molecules. By utilizing high-throughput screening technologies and modern imaging techniques, researchers can quickly and accurately analyze large numbers of compounds, capturing complex cellular responses and providing more biologically relevant metrics for drug development.

MCE cell screening platform features over 500 cell lines and multiple organoid culture systems, covering more than 30 tumor types. It offers multiple methods for assessing cell viability, apoptosis, and cell cycle, including CCK8, CTG assays, and flow cytometry. Additionally, it enables the detection of cytokines and gene expression through ELISA and qPCR, which can provide comprehensive support for researchers to analyze the cellular function and new drug development.

Services Offered

Cell Viability Assays

Apoptosis Assays

Cell Cycle Analysis

Cytokine Detection

Gene Expression Analysis

Organoid Drug Screening

Advantages

Abundant Cell Line Resources

Diverse Detection Methods

Advanced and Fully Equipped Instruments

Customized, Cost-Effective Solutions

Stringent Data Privacy Management

Cell Viability Assay

Cell viability refers to the ability of cells to maintain growth, reproduction, and physiological functions under both physiological and environmental conditions. It is closely related to the survival status, proliferative capacity, metabolic activity, and functional state of the cells. In cell biology research and drug development, cell viability serves as a critical assessment metric, as it reflects the health status of cells following exposure to various stimuli or drug treatments. This metric is widely used in fields such as anticancer drug screening and drug toxicity testing.

Common methods for assessing cell viability include CCK-8 and CTG assays. By evaluating the effects of drugs on cell viability and proliferation, researchers can rapidly assess the anticancer effects and toxicity of potential drug candidates.

Apoptosis Assay

Apoptosis, also known as programmed cell death, is a gene-regulated process of active cell death that plays a vital role in normal biological development and disease resistance. Dysregulation of apoptosis is closely linked to the onset and progression of various diseases, including tumors, neurodegenerative disorders, and autoimmune diseases.

The process of cell apoptosis exhibits obvious morphological characteristics, including cell shrinkage, cell membrane phosphatidylserine (PS) eversion, protein cleavage, chromatin condensation, and internucleosome DNA fragmentation, which ultimately lead to the formation of apoptotic bodies. Using flow cytometry, apoptotic detection markers can be combined with cell phenotype markers, allowing for the observation of changes in cell subpopulations. By employing fluorescently labeled Annexin V as a fluorescent probe, along with nuclear stains such as PI, 7-AAD, and DAPI, researchers can accurately differentiate between normal cells, early apoptotic cells, late apoptotic, and necrotic cells.

Cell Cycle Analysis

The cell cycle consists of the interphase and the mitotic phase. Interphase is further subdivided into G0 phase, G1 phase, S phase, and G2 phase, while the mitotic phase is referred to as M phase. During interphase, the cell grows and its nuclear DNA is duplicated. Interphase is followed by the mitotic phase. During the mitotic phase, the duplicated chromosomes are segregated and distributed into daughter nuclei. One of the most common methods for detecting the cell cycle is to stain the DNA within cells using Propidium Iodide (PI) and measure DNA content with flow cytometry.

Organoid Drug Screening

Organoids are three-dimensional (3D) tissue-like structures that are formed through the in vitro culture of adult or pluripotent stem cells. Although organoids are not true human organs, they can closely mimic the structure and function of real organs and can be stably passed over long periods. Many organoids can undergo extensive expansion in culture while maintaining genomic stability, making them particularly suitable for drug screening. They provide a more physiologically relevant representation of cellular composition and behavior compared to traditional 2D cell cultures and have been widely utilized in the field of anticancer drug screening.

MCE continuously optimizes culturing methods and has successfully developed organoid culture systems that encompass various cancer types, including lung cancer, liver cancer, head and neck cancer, gastric cancer, and colorectal cancer. These organoid systems can be used to evaluate the efficacy of protein drugs or small molecules, thereby accelerating the drug development process.

MCE tumor cell lines (partial)

Disease Cell Line
Bladder cancer 5637;647V;HT1197;HT1376;J82;KU1919;RT112;RT4;SCaBER;SW1710;SW780;T24;TCCSUP;UMUC3;
Brain Cancer A172;IMR32;KP-N-YN;LN18;LN229;NB1;SF268;SH-SY5Y;SK-N-AS;SK-N-BE(2);SK-N-SH;SW1088;U87 MG;U251
Bone Cancer SW1353;U2OS
Breast Cancer BT20;BT474;BT483;CAL148;CAMA1;EFM19;HCC1187;HCC1395;HCC1419;HCC1500;HCC1569;HCC1599;HCC1806;HCC1937;HCC1954;HCC202;HCC2218;HCC38;HCC70;Hs578t;JimT1;MCF7;MDAMB157;MDAMB231;MDAMB361;MDAMB453;MDAMB468;SKBR3;SUM159;T47D;ZR751;
Cervical Cancer C33A;CASKI;Hela;ME180;MS751;SiHa
Colorectal Cancer Caco2;COLO201;COLO205;COLO320DM;COLO678;DLD1;GP2d;HCT116;HCT15;HCT8;HT29;LoVo;LS174T;LS513;NCIH508;NCIH747;RKO;SNU407;SW1116;SW403;SW48;SW480;SW620;SW837;WiDR
Duodenal Cancer Hutu80
Endometrial Cancer AN3CA;HEC1A;HEC1B;MFE280;MFE296;RL95-2
Esophageal Cancer KYSE520
Gastric Cancer AGS;Hs746T;KATOIII;MKN1;MKN45;NCIN87;NUGC3;NUGC4;OCUM1;SNU1;SNU16;SNU5;SNU620;SNU668
Head and Neck Cancer CAL27;SCC9
Kidney Cancer 293T;786o;A498;ACHN;Caki2;G401
Laryngeal Cancer SNU899
Leukemia CCRFCEM;HL60;HPB ALL;Jurkat;K562;Kasumi1;Kasumi6;KG1;KOPN8;ML2;MOLM13;MOLT4;MV411;NALM6;RS411;SKM1;THP1;U937
Liver Cancer HEP3B;HepG2;HLE;HUH7;JHH7;MHCC97L;PLC/PRF/5;SKHEP1;SNU182
Lung Cancer A427;A549;BEAS-2B;CAL12T;Calu1;Calu3;Calu6;DMS114;DMS53;EBC1;HCC2935;HCC4006;HCC827;MSTO211H;NCIH1048;NCIH1092;NCIH1299;NCIH1395;NCIH146;NCIH1563;NCIH1573;NCIH1581;NCIH1650;NCIH1666;NCIH1792;NCIH1836;NCIH1882;NCIH1930;NCIH1944;NCIH1975;NCIH2009;NCIH2052;NCIH209;NCIH211;NCIH2110;NCIH2122;NCIH2228;NCIH226;NCIH2452;NCIH292;NCIH3122;NCIH322;NCIH358;NCIH441;NCIH446;NCIH460;NCIH520;NCIH522;NCIH524;NCIH526;NCIH647;NCIH661;NCIH69;NCIH838;NCIH841;NCIH889;PC9;SHP77;SKLU1;SKMES1;WI38
Lymphoma Daudi;DOHH2;Farage;H9;HUT102;Hut78;JeKo1;Karpas299;Karpas422;MAVER1;Mino;Namalwa;OCILY1;OCILY19;Pfeiffer;Raji;Ramos(RA-1);REC1;SR;SUDHL1;SUDHL6;SUDHL8;SUDHL10;Toledo;U2932;WSUDLCL2;Z138
Myeloma KMS11;KMS34;MM1S;MOLP8;NCIH929;RPMI8226;U266B1
Ovary Cancer A2780;CAOV3;ES2;IGROV1;MDAH2774;OV90;OVCAR3;OVCAR8;PA1;RKN;RMG1;SKOV3;TOV112D;TOV21G;UWB1289
Pancreas Cancer ASPC1;BxPC3;Capan1;Capan2;HPAC;HPAFII;HUPT3;KP4;Miapaca2;PANC04.03;PANC1;PK59;PSN1;QGP1;SU.86.86;SW1990
Papilloma KB
Prostate Cancer 22RV1;DU145;LNCap clone FGC;PC3
Sarcoma HT1080
Skin Cancer A375;A431;C32;G361;MDAMB435S;MeWo;SKMEL2;SKMEL5;SKMEL28;WM115
Squamous Cell Carcinoma UPCISCC090
Thyroid Cancer CAL62

MCE technicians have a wealth of experience, efficiently and accurately complete the various tests to ensure that the experimental data is accurate and reliable, and ultimately provide detailed and complete reports. We can also customize cost-effective solutions to meet specific needs. For more information regarding pricing or technical details, please email sales@medchemexpress.com or contact MCE sales directly.

Compound
Screening Libraries
Download
Compound Customization
  • Specific Compounds
  • Quantities
  • Plate Map
  • Concentration
  • Form (Solid or Solution)
  • YES
Contact Us for Customization